Brokers Offer Predictions for Zimmer Biomet FY2024 Earnings

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Stock analysts at Zacks Research dropped their FY2024 EPS estimates for shares of Zimmer Biomet in a note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $7.98 per share for the year, down from their previous estimate of $7.99. The consensus estimate for Zimmer Biomet's current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet's Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.38 EPS, FY2025 earnings at $8.51 EPS, Q3 2026 earnings at $2.21 EPS and FY2026 earnings at $9.18 EPS.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the business posted $1.65 EPS. The firm's revenue was up 4.1% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the stock. Wolfe Research initiated coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They issued a "peer perform" rating for the company. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Canaccord Genuity Group dropped their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating for the company in a research report on Tuesday, September 10th. Robert W. Baird dropped their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research report on Thursday, August 8th. Finally, TD Cowen dropped their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating for the company in a research report on Friday, September 6th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $123.22.

Zimmer Biomet Stock Up 1.5 %

ZBH stock traded up $1.61 during trading on Friday, reaching $110.01. The stock had a trading volume of 864,035 shares, compared to its average volume of 1,495,007. Zimmer Biomet has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $21.90 billion, a P/E ratio of 20.61, a PEG ratio of 2.04 and a beta of 1.02. The firm has a fifty day moving average price of $106.71 and a 200 day moving average price of $109.85.

Institutional Investors Weigh In On Zimmer Biomet

Large investors have recently made changes to their positions in the company. Seven Eight Capital LP acquired a new position in Zimmer Biomet in the 1st quarter valued at approximately $296,000. Bessemer Group Inc. increased its stake in Zimmer Biomet by 13.0% in the 1st quarter. Bessemer Group Inc. now owns 4,220 shares of the medical equipment provider's stock valued at $557,000 after buying an additional 487 shares during the period. Pitcairn Co. increased its stake in Zimmer Biomet by 17.2% in the 1st quarter. Pitcairn Co. now owns 2,657 shares of the medical equipment provider's stock valued at $351,000 after buying an additional 389 shares during the period. Crewe Advisors LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at approximately $31,000. Finally, EP Wealth Advisors LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter worth $282,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet's dividend payout ratio is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.